[New directions in GABAergic pharmacology of anxiety and depression].
New prospects in the use of drugs affecting central GABAergic system for the treatment of anxiety and depressive states are critically assessed. Both clinical (human) and experimental (animal) data on the mutual influence of various GABA-receptor modulators as well as the interaction of GABAergic system with neurohumoral mechanisms of stress are considered. Based on this analysis, new strategies in the GABAergic pharmacotherapy of anxiety and depression spectrum disorders are outlined.
Kaluev
A V
AV
Nutt
D D
DD
D000818:Animals; D001008:Anxiety Disorders / Q000188:drug therapy* / Q000503:physiopathology; D003866:Depressive Disorder / Q000188:drug therapy* / Q000503:physiopathology; D018756:GABA Antagonists / Q000627:therapeutic use*; D018757:GABA Modulators / Q000627:therapeutic use*; D006801:Humans; D009480:Neuropharmacology / Q000639:trends*; D018079:Receptors, GABA / Q000378:metabolism; D005680:gamma-Aminobutyric Acid / Q000378:metabolism*
D018756:GABA Antagonists; D018757:GABA Modulators; D018079:Receptors, GABA; D005680:gamma-Aminobutyric Acid